Apalutamide-d4
| Chemical Name | Apalutamide-d4 |
|---|---|
| Alternate Names | Apalutamide Stable Isotopes, Stable Isotopes of Apalutamide |
| CAT No. | CS-O-37738 |
| CAS Registry# | Not Available |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | 481.46 g/mol |
| Mol. For. | C21H11D4F4N5O2S |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Apalutamide |
| Smileys | O=C(C1(N(C2=S)C3=CC(F)=C(C=C3)C(NC)=O)C([2H])([2H])CC1([2H])[2H])N2C4=CN=C(C(C(F)(F)F)=C4)C#N |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Apalutamide-d4 is a deuterated form of the drug apalutamide, which is used as an androgen receptor inhibitor in the treatment of prostate cancer. The deuterium substitution in apalutamide-d4 enhances its pharmacokinetic properties, increasing its stability and prolonging its half-life, which may lead to improved therapeutic efficacy.
The mechanism of action of apalutamide-d4 is based on its ability to bind to the androgen receptor, blocking the action of androgens and inhibiting the growth and proliferation of prostate cancer cells. Apalutamide-d4 is administered orally in the form of tablets, usually once a day, and is taken in combination with other medications as part of a comprehensive treatment plan.
The chemical formula of apalutamide-d4 is C21H15D4F4N3O4S, and its molecular weight is 465.53 g/mol. The drug is a white to off-white crystalline powder, which is practically insoluble in water, but soluble in organic solvents such as ethanol and methanol.
Like other medications, apalutamide-d4 may cause side effects such as fatigue, nausea, diarrhea, and headache. Patients should be closely monitored for any signs of adverse reactions and advised to report any concerns to their healthcare provider. Overall, apalutamide-d4 represents an important advancement in the treatment of prostate cancer, and its deuterium substitution may offer new possibilities for improving patient outcomes and quality of life.
Get an Instant Quote
Related Compounds
N-Desmethyl apalutamide 13C2,15N | Apalutamide-13C-D3 | Apalutamide D7 |